Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging

Zieker, Derek; Königsrainer, Ingmar; Weinreich, J; Beckert, Stefan; Glatzle, Jörg; Nieselt, Kay; Bühler, Sarah; Löffler, Markus; Gaedcke, Jochen; Northoff, Hinnak; Mannheim, Julia G.; Wiehr, Stefan; Pichler, Bernd J.; Weyhern, Claus von; Brücher, Björn L.D.M.; Königsrainer, Alfred

doi:10.1159/000320545

Cited by 38 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[21][22][23] Interestingly, the high expression of PGK-1 is significantly correlated with tumor progression, metastasis and multidrug resistance in various cancers. 21,22,[24][25][26] It has also been reported that the expression of PGK-1 in PCa cells could induce bone formation 27 and that cancer-associated fibroblasts, which showed strong expression of PGK-1, could promote PCa growth, 28 suggesting that PGK-1 plays important roles in PCa development, progression and bone metastasis. In addition, both PGK-1 and AR genes are located within Xqll-Xql3 region and PGK-1 short tandem repeat polymorphism linkage to AR in the expression of miR-29a has been found to be correlated with short survival, more invasive phenotype, and early recurrence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…In addition, upregulated expression of PGK-1 in tumors has been correlated with metastatic phenotype of tumor. 22,23,25 Thus, downregulation of PGK-1 through epigenetic regulation by isoflavone could be another molecular mechanism by which isoflavone would be able to inhibit PCa invasion. However, more mechanistic studies are warranted.…”

Section: Methodsmentioning

confidence: 99%

Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Zieker et al (15) have shown that the excellent soft-tissue contrast of MR imaging permits the delineation of cancerous tissue within normal tissue; they emphasized the importance of such assessments for the quantification of PET tracer uptake in a metastatic mouse model mimicking human gastric cancer. For instance, identifying the tumor component of anatomic masses is important to quantify 18 F-FDG uptake in intestinal and hepatic lesions, where low lesion-to-background activity ratios are expected.…”

Section: Pet/mr Imaging In Preclinical Oncologymentioning

confidence: 99%

“…For instance, arterial spin labeling MR imaging and 15 O-H 2 O PET still lack cross-validation. The gold standard for the assessment of cerebral blood flow is 15 O-H 2 O PET (57). The value of arterial spin labeling MR imaging is controversial (58).…”

Section: Pet/mr Imaging As a Research Tool In Neurologymentioning

confidence: 99%

“…PET plays a key role in measuring the cerebral metabolic rate of oxygen using radioactive gases (59). However, because of the short half-life of 15 O, the 15 O technique requires an elaborate experimental setup with an on-site cyclotron. Moreover, the handling of radioactive gases requires special attention to reduce radiation exposure.…”

Section: Pet/mr Imaging As a Research Tool In Neurologymentioning

confidence: 99%

See 1 more Smart Citation

Preclinical and Translational PET/MR Imaging

et al. 2014

Self Cite

View full text Add to dashboard Cite

Combined PET and MR imaging (PET/MR imaging) has progressed tremendously in recent years. The focus of current research has shifted from technologic challenges to the application of this new multimodal imaging technology in the areas of oncology, cardiology, neurology, and infectious diseases. This article reviews studies in preclinical and clinical translation. The common theme of these initial results is the complementary nature of combined PET/MR imaging that often provides additional insights into biologic systems that were not clearly feasible with just one modality alone. However, in vivo findings require ex vivo validation. Combined PET/MR imaging also triggers a multitude of new developments in image analysis that are aimed at merging and using multimodal information that ranges from better tumor characterization to analysis of metabolic brain networks. The combination of connectomics information that maps brain networks derived from multiparametric MR data with metabolic information from PET can even lead to the formation of a new research field that we would call cometomics that would map functional and metabolic brain networks. These new methodologic developments also call for more multidisciplinarity in the field of molecular imaging, in which close interaction and training among clinicians and a variety of scientists is needed. Mol ecular imaging of small animals for biomedical research is an emerging field (1). It penetrates successfully into areas that are historically dominated by ex vivo molecular biology methods and therefore bears an enormous potential. Exploiting the full range of options of noninvasive visualization and quantification of metabolism, disease-specific dysfunction, therapy response, and cell trafficking requires that specific biomarkers yield information about molecular and functional processes as well as morphologic details. Single-modality imaging, such as stand-alone PET, SPECT, MR imaging, CT, or ultrasound, is often unable to provide the desired comprehensive information. Dedicated small-animal PET/CT and SPECT/CT scanners have been well received in the biomedical imaging sciences and have set the stage for a new combined imaging modality, PET/MR imaging, which has been introduced and successfully applied in biomedical studies (2,3). PET and MR imaging are both distinct modalities offering great versatility for advanced imaging applications in various fields of biomedicine. The combination of these two modalities into a single device merges functional and morphologic information from MR imaging with molecular PET data. The strength of PET lies in its high detection sensitivity and accurate quantification, but PET lacks good spatial resolution and tissue contrast. MR imaging, however, enables highresolution imaging of morphology with good soft-tissue contrast, detects endogenous metabolite distributions using spectroscopy, and allows dynamic acquisition of tissue perfusion and additional functional parameters (4).Thus, PET/MR imaging paves the way for noninvasive imaging to...

show abstract

Anticancer Agents That Counteract Tumor Glycolysis

2012

View full text Add to dashboard Cite

Can we consider cancer as a “metabolic disease”? Tumors are the result of a metabolic selection, forming tissues composed of heterogeneous cells that generally express an overactive metabolism as a common feature. In fact, cancer cells have to deal with increased needs for both energy and biosynthetic intermediates, in order to support their growth and invasiveness. However, their high proliferation rate often generates regions that are not sufficiently oxygenated. Therefore, their carbohydrate metabolism has to rely mostly on a glycolytic process that is uncoupled from oxidative phosphorylation. This metabolic switch, also known as the “Warburg Effect”, constitutes a fundamental adaptation of the tumor cells to a relatively hostile environment, and supports the evolution of aggressive and metastatic phenotypes. As a result, tumor glycolysis may constitute an attractive target for cancer therapy. This approach has often raised concerns that anti-glycolytic agents may cause serious side effects on normal cells. Actually, the key for a selective action against cancer cells can be found in their hyperbolic addiction to glycolysis, which may be exploited to generate new anti-cancer drugs showing minimal toxicity. In fact, there is growing evidence that supports many glycolytic enzymes and transporters as suitable candidate targets for cancer therapy. Herein we review some of the most relevant anti-glycolytic agents that have been investigated so far for the treatment of cancer.

show abstract

Phosphoglycerate Kinase 1 Promoting Tumor Progression and Metastasis in Gastric Cancer - Detected in a Tumor Mouse Model Using Positron Emission Tomography/Magnetic Resonance Imaging

Cited by 38 publications

References 18 publications

Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion

Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion

Preclinical and Translational PET/MR Imaging

Anticancer Agents That Counteract Tumor Glycolysis

Contact Info

Product

Resources

About